Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


A new 2013 research report extends the benefit of BLIS K12™

From: BLIS Technologies Ltd (NZX:BLT)

MediaPak: National Pak

Date: Friday, 11 Dec 2013

Release: Immediate

A new 2013 research report extends the benefit of BLIS K12™ probiotic

BLIS Technologies Ltd (NZX:BLT) announces another clinical study, just published this month, which further supports the effectiveness of BLIS K12™ oral cavity probiotic for preventing ear and throat infections. Published in the medical science journal, Expert Opinion on Biological Therapy, an Italian research team demonstrated that they could prevent the reoccurrence of common ear and throat infections, such as strep throat infection and tonsillitis by more than 83% in adults. The study followed 40 adults with a history of recurrent ear and throat infection and examined the effect of 90 days of treatment with either the BLIS K12™ probiotic or a placebo. Researchers concluded “The regular use of BLIS K12 appears to have effected a substantial reduction in the incidence of recurrent oral streptococcal pathology, reducing the requirement for these BLIS K12-treated individuals to be exposed to therapeutic courses of antibiotics.”

Di Pierro, F., et al. (2013). Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opinion on Biological Therapy.

This paper has been published just two months after a similar research paper also concluded that regular use of BLIS K12 in children could reduce the incidence of strep throat infection (including tonsillitis) by more than 92%. The children examined in this earlier study, previously had a recurrence rate for strep throat infection of nearly 4 times per year, however those children who then were assigned to the treatment with the BLIS K12™ probiotic dropped dramatically their rate of infection to the equivalent of just one incidence, every 4 years.

BLIS Technologies CEO, Dr Barry Richardson said, “We have known from our own work over several years about the effectiveness of the BLIS K12™ probiotic in treating and preventing certain infections of the throat and upper airways but finally, we have an independent research group that has now corroborated these findings. It is reassuring to us to know that BLIS K12™ has been independently supported as being highly efficacious in both children and adults.”

Dr Richardson said that he has seen a growing awareness among healthcare professional in New Zealand, pharmacists, dentist and doctors of benefits of BLIS K12™ probiotic for mouth and throat and has seen an increasing acceptance to consider BLIS K12™ probiotic as an option when managing the health of their patients, both young and old.

www.blis.co.nz

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Taxing Multinationals: EU Ruling Sours Apple

Shares of Apple slid, down 0.9 percent as of 3.08pm in New York, after the European Commission ruled that Ireland granted the company undue tax benefits of up to 13 billion euros (US$14.5 billion)—"illegal aid” under EU rules that the commission says Ireland now must recover from Apple. More>>

ALSO:

NZX Review: Best Practice Code Recommends Code Of Ethics

NZX, the sharemarket operator, is seeking feedback on proposed changes to its corporate governance best practice code including a published code of ethics, rules about share trading and continuous disclosure, and more transparency over board appointments and chief executive pay. More>>

ALSO:

Auditors:

Signs Of Life? SETI On Russian Space(?) Signal

A star system 94 light-years away is in the spotlight as a possible candidate for intelligent inhabitants, thanks to the discovery of a radio signal by a group of Russian astronomers... Could it be a transmission from a technically proficient society? At this point, we can only consider what is known so far. More>>

Post-Post: Brian Roche To Step Down As NZ Post CEO

Brian Roche will step down as chief executive of New Zealand Post in April 2017, having led the state-owned postal service's drive to adjust to shrinking mail volumes with a combination of cost cuts, asset sales, modernisation and expansion of new businesses. More>>

ALSO:

Company Results: Air NZ Rides The Tourism Boom With Record Full-Year Earnings

Air New Zealand has ridden the tourism boom and staved off increased competition to deliver the best full-year earnings in its 76-year history. More>>

ALSO:

New PGP: Sheep Milk Industry Gets $12.6M Crown Funding

The Sheep - Horizon Three programme aims to develop "a market driven, end-to-end value chain generating annual revenues of between $200 million and $700 million by 2030," according to a joint statement. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news